Morepen Laboratories Beheer
Beheer criteriumcontroles 3/4
De CEO Morepen Laboratories is Sushil Suri, benoemd in Oct2000, heeft een ambtstermijn van 24.08 jaar. bezit rechtstreeks 1.22% van de aandelen van het bedrijf, ter waarde ₹ 496.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.9 jaar en 4.8 jaar.
Belangrijke informatie
Sushil Suri
Algemeen directeur
₹39.1m
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 24.1yrs |
| Eigendom CEO | 1.2% |
| Management gemiddelde ambtstermijn | 7.9yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹1b |
| Jun 30 2024 | n/a | n/a | ₹1b |
| Mar 31 2024 | ₹39m | n/a | ₹962m |
| Dec 31 2023 | n/a | n/a | ₹761m |
| Sep 30 2023 | n/a | n/a | ₹531m |
| Jun 30 2023 | n/a | n/a | ₹477m |
| Mar 31 2023 | ₹48m | ₹44m | ₹387m |
| Dec 31 2022 | n/a | n/a | ₹428m |
| Sep 30 2022 | n/a | n/a | ₹553m |
| Jun 30 2022 | n/a | n/a | ₹768m |
| Mar 31 2022 | ₹91m | ₹87m | ₹1b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹54m | ₹51m | ₹971m |
| Dec 31 2020 | n/a | n/a | ₹814m |
| Sep 30 2020 | n/a | n/a | ₹684m |
| Jun 30 2020 | n/a | n/a | ₹453m |
| Mar 31 2020 | ₹17m | ₹16m | ₹336m |
| Dec 31 2019 | n/a | n/a | ₹331m |
| Sep 30 2019 | n/a | n/a | ₹312m |
| Jun 30 2019 | n/a | n/a | ₹340m |
| Mar 31 2019 | ₹12m | ₹11m | ₹288m |
| Dec 31 2018 | n/a | n/a | ₹252m |
| Sep 30 2018 | n/a | n/a | ₹267m |
| Jun 30 2018 | n/a | n/a | ₹308m |
| Mar 31 2018 | ₹6m | ₹4m | ₹296m |
Compensatie versus markt: De totale vergoeding ($USD 464.10K ) Sushil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 271.25K ).
Compensatie versus inkomsten: De vergoeding van Sushil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sushil Suri (60 yo)
24.1yrs
Tenure
₹39,112,000
Compensatie
Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 24.1yrs | ₹39.11m | 1.22% ₹ 496.2m | |
| Whole-Time Director | 9.8yrs | ₹21.80m | 1.01% ₹ 408.4m | |
| Chief Financial Officer | 10.3yrs | ₹9.80m | geen gegevens | |
| General Manager of Process Engineering & Technology Transfer | no data | geen gegevens | geen gegevens | |
| Manager of Administration | no data | geen gegevens | 0.58% ₹ 236.3m | |
| Company Secretary & Compliance Officer | 6yrs | ₹1.84m | geen gegevens | |
| Functional Head of Talent Acquisition & HRBP | less than a year | geen gegevens | geen gegevens | |
| Chief Operating Officer of API | less than a year | geen gegevens | geen gegevens | |
| Head of Medipath Division | no data | geen gegevens | 0.42% ₹ 168.9m | |
| Head of International Business Development | no data | geen gegevens | geen gegevens | |
| Chief Executive Officer of Consumer Division | no data | geen gegevens | 0.56% ₹ 225.9m | |
| Chief of R&D | no data | geen gegevens | geen gegevens |
7.9yrs
Gemiddelde duur
47.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MOREPENLAB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 32.8yrs | ₹39.11m | 1.22% ₹ 496.2m | |
| Whole-Time Director | 5.3yrs | ₹21.80m | 1.01% ₹ 408.4m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 5.3yrs | ₹520.00k | geen gegevens | |
| Independent Director | 4.4yrs | ₹300.00k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MOREPENLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).